The cardiovascular protection debate between two diabetes drug classes just gained crucial clarity for a vulnerable patient population. Adults with both fatty liver disease and type 2 diabetes face compounded cardiovascular risk, making optimal medication selection critical for preventing heart attacks, strokes, and premature death.
A comprehensive analysis of 52,094 patients revealed that glucagon-like peptide-1 receptor agonists delivered 14% lower cardiovascular event rates compared to SGLT2 inhibitors over three years of follow-up. The GLP-1 drugs demonstrated broad protective effects, reducing risks of heart failure, myocardial infarction, stroke, and all-cause mortality across multiple analytical approaches. This head-to-head comparison utilized sophisticated propensity matching to control for patient demographics, comorbidities, and laboratory variables.
This finding challenges assumptions about equivalent cardiovascular benefits between these drug classes. While both medication types have established cardiovascular protective effects in clinical trials, this real-world evidence suggests meaningful differences in patients with metabolic dysfunction-associated steatotic liver disease. The study's strength lies in its large sample size and robust methodology designed to minimize confounding factors that plague observational research.
However, limitations remain significant. The retrospective design cannot establish causation, and unmeasured confounders may influence outcomes. Additionally, the study period spans recent years when GLP-1 prescribing patterns evolved rapidly, potentially introducing selection bias. For clinicians treating this high-risk population, these results support prioritizing GLP-1 therapy while acknowledging that individual patient factors should guide treatment decisions.